Scabies Signs and Symptoms

Signs and Symptoms

Introduction

Diagnosis is made based on clinical presentation and can be confirmed by microscopic identification of mites, eggs or mite feces
Scabies should be suspected in a patient who presents with a highly pruritic rash with nocturnal predominance
- Scabies is highly suggested if there is also a history of contact with an infected person or if there is a history of contact with family member or sexual partner who has pruritic lesions with nocturnal predominance

Scabies is caused by the mite: Sarcoptes scabiei var hominis
Occurs more often in children <15 years, sexually active young adults, the immunocompromised and in persons living in crowded living conditions (eg nursing homes, military barracks)
Transmission is typically by direct skin contact with an infected person and in adults, sexual transmission is common
- Though there is limited documentation, transmission by fomites may be possible (especially in cases of crusted scabies where a large amount of parasites are involved)
- The mites can live for up to 30 days on a host and remain alive for 3 days on furniture, bedding, etc

Signs and Symptoms

Primary symptom is generalized pruritus, which is usually worse at night
- Pruritus is caused by a delayed (type IV) hypersensitivity reaction to the mite and its products (saliva, eggs and feces) once the host becomes sensitized
- Hypersensitivity occurs 3-6 weeks after infestation but occurs in 1-3 days with re-infestation because the host has been previously sensitized

ID NOW rapid molecular assay an effective COVID-19 test for kids

Rapid COVID-19 testing: Is it as good in kids?

Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Vaccination reduces risks of long-COVID and death

23 Aug 2023

COVID-19 vaccination can reduce the risk of long COVID if given before SARS-CoV-2 infection.

Findings suggest that vaccination before infection confers only partial protection in the post-acute phase of the disease. Hence, reliance on vaccination as a sole mitigation strategy may not optimally reduce long-term health consequences of SARS-CoV-2 infection.

Current management of nosocomial and community-acquired pneumonia in ICU patients with novel antibiotics

Prof. Andrew Shorr, 27 Aug 2021

Nosocomial pneumonia serves as a paradigm for all severe infections, and appropriate antibiotic therapy is the key determinant of patient outcomes. Most data for the use of antibiotics are derived from studies in non-ICU patients and ignore critical care issues such as fluid resuscitation, mechanical ventilation, and changing renal function. Against the backdrop of increasing antimicrobial resistance and the COVID-19 pandemic, how do we optimize antibiotic administration in the ICU? Professor Andrew Shorr from Washington Hospital Center, Georgetown University, Washington DC, US discussed this burning issue at a Pfizer-sponsored satellite symposium, held during the Asia Pacific Intensive Care Symposium (APICS) 2021.